“Cell-Based Assay market set to grow to $22bn by 2022” says new Visiongain report

18 September 2018
Pharma

Visiongain has launched a new pharma report Cell-Based Assays World Industry and Market 2018-2028: Drug Discovery, Basic Research, Predictive Technology, Instrument, Consumables, Software, Services, Reagents, Assay Kits, Microplates, Cell Lines, Probes & Labels, Pharma & Biotech Companies, Academic Institutes, CROs.

Cell-based assays hold a number of advantages over traditional biochemical assays and animal models, and these advantages have driven the increased demand for these assays in recent years. There has been an increased usage of cell-based assays as the preferred tool for screening potential drug compounds and toxicity screening, thus growing demand by drug development companies. The demand for cell-based assays will expand further due to increased allocation of resources towards drug discovery by companies, the presence of a large number of proteins which still have unknown functions, and the rising demand for biological drugs.

The lead analyst of the report commented "Whilst there are many factors driving growth in the cell-based assays market, market challenges still exist. Even though the cost of cell-based assays is gradually declining as the technology advances, the overall cost of cell-based assays and the equipment required to run them and analyse the data, is still high.

Another restraint is the complexity of cell-based assays, and the need for skilled individuals to run them and to analyse the data from them. The complexities of these assays also mean that the development of innovative new assays and products by cell-based assay companies is costly and can take a long time."

Leading companies featured in the report include BD (Becton, Dickinson and Company), BioAgilytix Labs, BioVision, Cell Assay Innovations, Inc., Charles River Laboratories International, CYTOO SA, DiscoverX, GE Healthcare, InSphero,Marin Biological Laboratories, Molecular Devices, Perkin Elmer, Pharmaceutical Product Development, Porsolt, Promega, ProQinase GmbH, QGel, SGS Group, Inc., Thermo Fisher Scientific (and Affymetrix acquisition)

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

Read

“Global Oncology Drugs market set to grow to $173bn by 2024” says new Visiongain report

The cancer treating drugs market will continue to grow over the next ten years.

03 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1